High KLK7 mRNA expression indicated unfavorable PFS for all patients with ovarian cancer (HR, 1.67; 95% CI, 1.38–2.02; P = 1.3 × 10−07; Figure 6a), patients with serous ovarian cancer (HR, 1.43; 95% CI, 1.16–1.77; P = 0.00084; Figure 6b) and patients with endometrioid ovarian cancer (HR, 5.05; 95% CI, 1.74–14.65; P = 0.00095; Figure 6c). The gene discussed is KLK7; the disease is ovarian carcinoma.